No Data
Oric Pharmaceuticals Announces Clinical Trial Collaboration And Supply Agreement With Johnson & Johnson To Evaluate ORIC-114 In Combination With Subcutaneous Amivantamab For The First-Line Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations
Top Midday Stories: Trump Vows 100% Tariff on Foreign-Made Films; Buffett to Step Down As Berkshire CEO
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
Market Chatter: India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs
Was Jim Cramer Right About Johnson & Johnson (JNJ)?
Teva, Alvotech Get FDA Nod for Johnson & Johnson Biosimilar
loading...